Association between COVID-19 vaccination and bullous pemphigoid – a case series and literature review

Wan, Vincent; Chen, Dilys; Shiau, Carolyn J; Jung, Gordon W

doi:10.1177/2050313x221131868

Cited by 6 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Additionally, reactions between SARS-coV-2 spike protein antibodies and tissue protein transglutaminases have been implicated, possibly leading to BP development. 6 Similar to the study by Arduino et al, we find higher incidences of pemphigus in females, with pemphigus vulgaris being the most common subtype. 1 We observe similar overall trends in BP patients.…”

supporting

confidence: 91%

The role of COVID‐19 vaccines in the development and recurrence of pemphigus and bullous pemphigoid

Pathak,

Rao

2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

The role of COVID-19 vaccines in the development and recurrence of pemphigus and bullous pemphigoidDear Editor, We read with great interest the case-control study by Arduino et al., 1 regarding de novo pemphigus development post COVID-19 infection and vaccination. The original study has a small cohort for vaccination related cases (n = 9); in this study, additional data regarding pemphigus and bullous pemphigoid (BP) development post COVID-19 vaccination are evaluated.The Vaccine Adverse Events Reporting System (VAERS) is a national adverse event (AE) reporting system managed by the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC). 2 The VAERS

show abstract

supporting

confidence: 91%

The role of COVID‐19 vaccines in the development and recurrence of pemphigus and bullous pemphigoid

Pathak,

Rao

2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…It has been proposed that cross-reactivity between these particles leads to the development of autoimmune diseases such as bullous pemphigoid. 29 In our study, mRNA Covid-19 vaccine (Pfizer) was linked to BP. Pfizer vaccine is more often associated with vaccine-induced bullous pemphigoid than other mRNA-or vector-based vaccines.…”

Section: Discussionmentioning

confidence: 95%

Association Between Medication Use and Bullous Pemphigoid: A Ten-Year Systematic Review

Agnes Marpaung,

Retnawati Sihombing

2024

JARMHS

View full text Add to dashboard Cite

Background: Bullous pemphigoid is an autoimmune subepithelial disease. It was associated with autoantibodies targeting hemidesmosome protein BPAG1 and BPAG2. The incidence of bullous pemphigoid has increased 1.9-4.3 times in the past two decades, possibly due to increased life expectancy, medication use, and improved diagnostic methods. Trigger factors of BP included drugs, physical factors, radiotherapy, trauma, and thermal exposure. The aim: This study aims to determine association between medication use and bullous pemphigoid. Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2014 and 2024 were taken into account. Several different online reference sources, like Pubmed and ScienceDirect, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done. Results: In the PubMed database, the results of our search brought up 1,662 articles, whereas the results of our search on ScienceDirect brought up 1,143 articles. The results of the search conducted by title screening yielded a total of 13 articles for PubMed and 32 articles for ScienceDirect. We compiled a total of 26 papers, 8 of which came from PubMed and 18 of which came from ScienceDirect. We excluded 2 review articles, 1 duplicate article, 3 non-full text articles, and 3 articles having insufficient outcomes. In the end, we included seventeen research that met the criteria. Conclusion: Our study suggests that dipeptidyl peptidase-4 inhibitors and aldosterone antagonists are associated with BP. Other medications, such as immunomodulatory agents, anticonvulsants, tyrosine kinase inhibitors, antibiotics, anticoagulants, diuretics, and mRNA COVID-19 vaccine, may be associated with BP. Regarding these results, clinicians should pay close attention to prescribing the medicine to their patients.

show abstract

“…In the flare group, 92% of cases were classified as 'possible', and 8% as 'probable'. Notably, all cases deemed 'probable' in causality had experienced a disease flare following both doses of COVID-19 vaccines, contributing to the overall score for these cases [6,13,25,37,38,[40][41][42]49,50,53,54,68,71,75,86,91].…”

Section: The Assessment Of Naranjo Scores For New-onset Aibd or Aibd ...mentioning

confidence: 99%

“…In the new onset group, BP patients with limited involvement were treated with topical corticosteroids, while those with more extensive involvements received a variety of systemic immunomodulators, including corticosteroids, doxycycline, nicotinamide, methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide, dapsone, colchicine, or hydroxychloroquine [5,6,14,15,28,31,32,35,38,39,[42][43][44][45]49,51,53,56,[70][71][72][73]75,77,82,86,87,92,93]. DPP-4 inhibitors were suspended in patients using these medications [34,44,45,48].…”

Section: Treatment and Outcomes For New-onset Aibd Or Aibd Flaresmentioning

confidence: 99%

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

Wu,

Huang,

Wang

et al. 2024

Vaccines

View full text Add to dashboard Cite

Background: Cases of autoimmune bullous dermatosis (AIBD) have been reported following COVID-19 vaccination. Objective: We aimed to provide an overview of clinical characteristics, treatments, and outcomes of AIBDs following COVID-19 vaccination. Methods: We conducted a systematic review and searched the Embase, Cochrane Library, and Medline databases from their inception to 27 March 2024. We included all studies reporting ≥ 1 patient who developed new-onset AIBD or experienced flare of AIBD following at least one dose of any COVID-19 vaccine. Results: We included 98 studies with 229 patients in the new-onset group and 216 in the flare group. Among the new-onset cases, bullous pemphigoid (BP) was the most frequently reported subtype. Notably, mRNA vaccines were commonly associated with the development of AIBD. Regarding the flare group, pemphigus was the most frequently reported subtype, with the mRNA vaccines being the predominant vaccine type. The onset of AIBD ranged from 1 to 123 days post-vaccination, with most patients displaying favorable outcomes and showing improvement or resolution from 1 week to 8 months after treatment initiation. Conclusions: Both new-onset AIBD and exacerbation of pre-existing AIBD may occur following COVID-19 vaccination. Healthcare practitioners should be alert, and post-vaccination monitoring may be essential.

show abstract

Association between COVID-19 vaccination and bullous pemphigoid – a case series and literature review

Cited by 6 publications

References 19 publications

The role of COVID‐19 vaccines in the development and recurrence of pemphigus and bullous pemphigoid

The role of COVID‐19 vaccines in the development and recurrence of pemphigus and bullous pemphigoid

Association Between Medication Use and Bullous Pemphigoid: A Ten-Year Systematic Review

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

Contact Info

Product

Resources

About